{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-115713","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.551550+00:00","generated_at":"2026-06-22T03:50:41.409773+00:00","sec_items":["2.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Avenue Therapeutics completes acquisition of Baergic Bio and its CNS asset BAER-101","bullets":["Acquired majority of Baergic Bio shares from Fortress Biotech; Baergic now a subsidiary of Avenue.","Baergic's lead compound BAER-101 is a selective GABA-A α2/3 PAM in-licensed from AstraZeneca with safety data in over 700 patients.","Closing conditions included $7.5M equity raise and repurchase of InvaGen's shares in Avenue.","CEO Alexandra MacLean said BAER-101 has potential for orphan and larger CNS indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-115713","json":"https://secwatch.observer/filing/0001104659-22-115713.json","markdown":"https://secwatch.observer/filing/0001104659-22-115713.md","text":"https://secwatch.observer/filing/0001104659-22-115713.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/tm2229538d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:50:41.409773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7a88c18c890a7981320d53a1f0a8ab121d7a631","claim":"AVENUE THERAPEUTICS, INC. completed an acquisition involving Fortress Biotech, Inc. (closed 2022-11-08).","evidence_excerpt":"On November 8, 2022, following the satisfaction of the closing conditions of the Contribution Agreement, the Company completed the acquisition of a majority of the outstanding shares (common and preferred) of Baergic from Fortress.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465922115713/0001104659-22-115713-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Fortress Biotech, Inc."},{"label":"Closing","value":"2022-11-08"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}